Table 3.
Characteristics of participants providing individual participant data (continuous variables)
| Trial | Age (years) | Epilepsy duration (years) |
Number of seizures in the last 6 months |
|||||||
| Mean | SD | Range | Missing | Median | Range | Missing | Median | Range | Missing | |
| Banu 2007 | 5.7 | 3.5 | 1 to 15 | 0 | 1.2 | 0 to 11.5 | 0 | 24 | 1 to 7200 | 5 |
| Baulac 2012 | 36.4 | 15.9 | 18 to 75 | 0 | 0.2 | 0 to 17.7 | 30 | 2 | 1 to 30 | 1 |
| Bill 1997 | 26.8 | 10.7 | 15 to 91 | 1 | 0.4 | 0 to 25 | 0 | 3 | 0 to 252 | 0 |
| Biton 2001 | 32 | 14.5 | 12 to 76 | 0 | 1 | 0 to 53 | 27 | 2 | 0 to 100 | 2 |
| Brodie 1995a | 34 | 15.8 | 14 to 71 | 0 | 1 | 0 to 18 | 0 | 4 | 1 to 960 | 0 |
| Brodie 1995b | 30 | 14.1 | 14 to 81 | 0 | 0.5 | 0 to 19.4 | 0 | 3 | 1 to 1020 | 0 |
| Brodie 1999 | 76.9 | 6 | 65 to 94 | 0 | NA | NA | 150 | 3 | 0 to 163 | 0 |
| Brodie 2007 | 39 | 16.2 | 15 to 82 | 0 | NA | NA | 579 | 3 | 1 to 1410 | 4 |
| Chadwick 1998 | 35 | 16.6 | 12 to 86 | 0 | 0.5 | 0 to 7.7 | 5 | 4 | 1 to 146 | 6 |
| Craig 1994 | 78.2 | 7.1 | 61 to 95 | 3 | NA | NA | 166 | 3 | 0 to 99 | 3 |
| de Silva 1996 | 9.9 | 3.6 | 3 to 16 | 6 | 0.5 | 0 to 13.7 | 6 | 3 | 1 to 900 | 6 |
| Dizdarer 2000 | 10.8 | 2.3 | 4 to 15 | 0 | NA | NA | 52 | 3 | 1 to 60 | 0 |
| Eun 2012 | 8.8 | 2.1 | 5 to 13 | 0 | 0.4 | 0 to 4.5 | 0 | 3 | 2 to 11 | 0 |
| Guerreiro 1997 | 18.6 | 9.7 | 5 to 53 | 1 | 0.4 | 0 to 20 | 0 | 2 | 0 to 157 | 0 |
| Heller 1995 | 32.3 | 14.8 | 13 to 77 | 3 | 1 | 0 to 40 | 4 | 2 | 1 to 579 | 3 |
| Kwan 2009 | 33.9 | 10.9 | 16 to 56 | 0 | NA | NA | 81 | 1 | 0 to 540 | 0 |
| Lee 2011 | 35.8 | 12.2 | 16 to 60 | 0 | NA | NA | 110 | 2 | 0 to 200 | 0 |
| Mattson 1985 | 41 | 15.5 | 18 to 82 | 4 | 2 | 0.5 to 59 | 5 | 1 | 1 to 100 | 7 |
| Mattson 1992 | 47.1 | 16.1 | 18 to 83 | 0 | 3 | 1 to 68 | 19 | 12 | 1 to 2248 | 38 |
| Nieto‐Barrera 2001 | 27.2 | 21.4 | 2 to 84 | 1 | NA | NA | 622 | 3 | 1 to 9000 | 0 |
| Ogunrin 2005 | 27.5 | 8.5 | 14 to 55 | 0 | 7 | 3 to 11.5 | 18 | 12 | 6 to 42 | 0 |
| Pal 1998 | 11.4 | 5 | 2 to 18 | 0 | 2.5 | 0.5 to 17 | 2 | NA | NA | 94 |
| Placencia 1993 | 29 | 17.6 | 2 to 68 | 0 | 5 | 0.5 to 44 | 0 | 2 | 0 to 100 | 0 |
|
Privitera 2003 (CBZ branch)a |
34.4 | 18.4 | 6 to 80 | 0 | NA | NA | 395 | 4 | 0 to 2400 | 0 |
|
Privitera 2003 (VPS branch)a |
32.8 | 19.4 | 6 to 84 | 0 | NA | NA | 225 | 4 | 0 to 20000 | 0 |
| Ramsey 1992 | 20.9 | 14.2 | 3 to 64 | 0 | 0 | 0 to 3 | 0 | NA | NA | 136 |
| Ramsey 2010 | 34.1 | 14.8 | 12 to 78 | 0 | NA | NA | 261 | 4 | 0 to 570 | 0 |
| Reunanen 1996 | 32.1 | 14.2 | 12 to 72 | 2 | 0.7 | 0 to 27 | 3 | 3 | 1 to 145 | 1 |
| Richens 1994 | 33 | 14.9 | 16 to 79 | 2 | NA | NA | 300 | 4 | 2 to 101 | 5 |
| SANAD A 2007 | 38.4 | 18.3 | 5 to 86 | 44 | NA | NA | 1721 | 4 | 0 to 1185 | 49 |
| SANAD B 2007 | 22.5 | 14.1 | 5 to 77 | 14 | NA | NA | 716 | 3 | 0 to 2813 | 17 |
| Steiner 1999 | 34.1 | 16.7 | 13 to 75 | 1 | 1.3 | 0 to 28.5 | 1 | 3 | 1 to 600 | 0 |
| Stephen 2007 | 36 | 16.9 | 13 to 80 | 2 | NA | NA | 227 | 18 | 6 to 1080 | 37 |
|
Trinka 2013 (CBZ branch)1 |
42.8 | 17.2 | 16 to 89 | 0 | NA | NA | 999 | NA | NA | 999 |
|
Trinka 2013 (VPS branch)1 |
36.5 | 17.8 | 16 to 85 | 1 | NA | NA | 703 | NA | NA | 703 |
| Turnbull 1985 | 35.2 | 16.1 | 14 to 70 | 0 | 0.75 | 0.1 to 30 | 0 | 2 | 0 to 60 | 0 |
| Verity 1995 | 10.1 | 2.9 | 5 to 16 | 13 | 0.3 | 0 to 5.9 | 32 | 3 | 1 to 104 | 12 |
| Werhahn 2015 | 71.5 | 7.2 | 60 to 95 | 0 | NA | NA | 361 | 2 | 1 to 96 | 7 |
| Total (missing) | 98 | 7820 | 2135 | |||||||
Abbreviations: SD: Standard deviation
aTrials designed in two strata based on whether recommended treatment would be CBZ or VPS. Within the two strata, participants were randomised to TPM in Privitera 2003/LEV in Trinka 2013 or CBZ/VPS depending on the strata. Data analysed according to the separate strata (CBZ branch or VPS branch) in this review.